Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025

At the prestigious ENDO 2025 conference, Aviva Biopharm Inc. presented groundbreaking pre-clinical findings on d3-T, a pioneering testosterone therapy specifically designed for women. This innovative treatment promises to address a significant gap in hormone therapy options available for female patients, marking a potential turning point in women's health. The unveiling of d3-T has generated considerable excitement among healthcare professionals and researchers alike, as it aims to provide a safe and effective solution for women experiencing hormonal imbalances. The preliminary data showcased at the event highlights d3-T's unique formulation and its potential benefits, creating a buzz about the future of hormone therapies. As the medical community anticipates further developments, Aviva Biopharm Inc. is poised to lead the charge in revolutionizing women's healthcare with this first-in-class therapy, paving the way for more tailored treatments in the realm of hormone management.